WallStreetZenWallStreetZen

NASDAQ: CHRS
Coherus Oncology Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Coherus Oncology revenue was $197.50M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q1 2025) ending on Mar 31, 2025 was $7.6M, down 86% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, CHRS annual revenue was $267.0M, with 3.8% growth year-over-year.

CHRS past revenue growth

How has CHRS's revenue growth performed historically?

Company
-13.04%
Industry
150.01%
Market
20.37%
CHRS's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
CHRS's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
CHRS's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

CHRS revenue history

Current Revenue
$197.5M
Current Earnings
-$130.9M
Current Profit Margin
-66.3%

Be the first to know when CHRS announces revenue.

CHRS Revenue History By Year

CHRS Yearly RevenueCHRS RevenueCHRS ChangeCHRS Revenue Growth
2024-12-31$266.96M$9.72M+3.78%
2023-12-31$257.24M$46.20M+21.89%
2022-12-31$211.04M-$115.51M-35.37%
2021-12-31$326.55M-$149.27M-31.37%
2020-12-31$475.82M$119.75M+33.63%
2019-12-31$356.07MN/AN/A
2018-12-31$0.00-$1.56M-100.00%
2017-12-31$1.56M-$188.55M-99.18%
2016-12-31$190.11M$160.07M+532.82%
2015-12-31$30.04M-$1.07M-3.42%
2014-12-31$31.11M$28.36M+1,030.72%
2013-12-31$2.75M$852.00k+44.87%
2012-12-31$1.90MN/AN/A

1 of 1

Coherus Oncology Revenue FAQ

What was CHRS's revenue last quarter?

On Invalid Date, Coherus Oncology (NASDAQ: CHRS) reported Q1 2025 revenue of $7.60 million up 229.25% year over year. In the same quarter last year, Coherus Oncology's revenue was $2.31 million.

What was Coherus Oncology's revenue in 2024?

Coherus Oncology's annual revenue for the twelve months ending Dec 31, 2024 was $266.96 million, a 3.78% increase year over year.

How much does Coherus Oncology make in a day?

Based on Coherus Oncology annual revenue for the past five years, CHRS makes an average of $842,532.05 per day.

What was Coherus Oncology's annual revenue growth in the past year?

As of Q4 2025, Coherus Oncology's revenue has grown -13.04% year over year. This is 163.05 percentage points lower than the US Biotechnology industry revenue growth rate of 150.01%. Coherus Oncology's revenue in the past year totaled $197.50 million.

How much does Coherus Oncology make in a year?

Coherus Oncology's revenue by year for the past five years is:
  • Coherus Oncology's revenue for the twelve months ending Dec 31, 2024 was $266.96 million, a 3.78% increase year over year.
  • Coherus Oncology's annual revenue for Dec 31, 2023 was $257.24 million, a 21.89% increase from 2022.
  • Coherus Oncology's annual revenue for 2022 was $211.04 million, a 35.37% decrease from 2021.
  • Coherus Oncology's annual revenue for 2021 was $326.55 million, a 31.37% decrease from 2020.
  • Coherus Oncology's annual revenue for 2020 was $475.82 million, a 33.63% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.